PharmaGap appoints advisory researcher

By Elaine Rigoli

Tampa, Fla., Sept. 15 - PharmaGap, Inc. has completed arrangements with Gary K. Schwartz of Memorial Sloan - Kettering Cancer Center in New York to act as adviser to, and collaborator with, PharmaGap on its drug-development program targeting Protein Kinase C isoforms of therapeutic and clinical interest.

"The initial compound developed by PharmaGap addresses a significant unmet need in oncology - namely specifically targeting individual isoforms of PKC [Protein Kinase C] believed to be implicated in tumor development, such as PKCalpha. I am looking forward to working with this innovative company in assessment and further development of this unique compound, and to assist PharmaGap in getting the compound into clinical use," Schwartz said in a news release.

Schwartz will advise and collaborate with PharmaGap researchers in experimental design and execution designed initially to take the company's lead cancer drug compound - PhGalpha1- from the laboratory into human clinical trials.

PharmaGap is an Ottawa, Ont., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.